Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Treatment of adult short bowel syndrome patients with teduglutide

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pharmacotherapeutic considerations in women with multiple sclerosis

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftReviewpeer review

  3. Irinotecan and bevacizumab in recurrent glioblastoma multiforme

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Therapeutic management of type 1 diabetes before and during pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  5. Treating tension-type headache -- an expert opinion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
INTRODUCTION: Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may cause impairment of the quality of life of SBS-IF patients. Conventional treatments include dietary manipulations, oral rehydration solutions, antidiarrheal and antisecretory treatments. However, the evidence base for these interventions is limited, and treatments improving structural and functional integrity of the remaining intestine are desired. Teduglutide , an analog of glucagon-like peptide 2, improves intestinal rehabilitation by promoting mucosal growth and possibly by inhibiting gastric emptying and secretion, which in turn reduces intestinal losses and promotes intestinal absorption. AREAS COVERED: This paper reviews the following findings: in a 3-week, Phase II balance study, teduglutide reduced diarrhea by ∼ 700 g/day and fecal energy losses by ∼ 0.8 MJ/day, and in a randomized, placebo-controlled, 24-week, Phase III study, corresponding reductions in the need for parenteral support were obtained. EXPERT OPINION: Teduglutide seems to be safe and well-tolerated and demonstrates restoration of structural and functional integrity of the remaining intestine with significant intestinotrophic and proabsorptive effects, facilitating a reduction in diarrhea and an equivalent reduction in the need for parenteral support in SBS-IF patients.
OriginalsprogEngelsk
TidsskriftExpert Opinion on Pharmacotherapy
Vol/bind13
Udgave nummer2
Sider (fra-til)235-43
Antal sider9
ISSN1465-6566
DOI
StatusUdgivet - 2012

ID: 36794726